Our experimental results may thus suggest that c-MET tyrosine kinase inhibitors could be successfully utilized to induce CLL cells death as well as to block CLL/accessory cells interactions that support survival of the leukemic B cell clone (Figure 3). Here, MET is linked to B-cell chronic lymphocytic leukemia.